Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback